Arvelle Therapeutics GmbH

https://www.arvelletx.com

Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders. Arvelle is responsible for the development and commercialization of cenobamate, an investigational antiepileptic drug, in the European market. Arvelle is headquartered in Switzerland and received one of the largest initial financing commitments for a European-focused biopharmaceutical company with investments from a global syndicate including NovaQuest Capital Management, LSP, BRV Capital Management, Andera Partners and H.I.G. BioHealth Partners. *

	Start	2019-02-14 established (approx)
	Industry	CNS drug
	Industry 2	cenobamate
	Person	Altmeyer, Mark (Arvelle Therapeutics 201902– CEO before Axovant Sciences + BMS + Otsuka America Pharmaceutical)

	Region	Basel BS
	Country	Switzerland
	Street	8 Viaduktstr.
	City	4051 Basel BS
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for ï¿½About Sectionï¿½: Arvelle Therapeutics GmbH. (2/14/19). "Press Release: Newly-Formed Arvelle Therapeutics Acquires Exclusive Rights from SK Biopharmaceuticals to Develop and Commercialize Cenobamate in Europe". Basel.

		Record changed: 2020-09-26

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Arvelle Therapeutics GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]